oestradiol valerate + medroxyprogesterone acetate

This hormone therapy is a sequential combination regimen used as an adjuvant treatment following hysteroscopic adhesiolysis for intrauterine adhesions (Asherman's syndrome). It consists of high-dose oestradiol valerate (6 mg/day) to stimulate endometrial proliferation and re-epithelialization of the uterine cavity, followed by the addition of medroxyprogesterone acetate (6 mg/day) to induce a withdrawal bleed. This regimen aims to prevent the reformation of adhesions and improve fertility outcomes. In the context of the Sir Run Run Shaw Hospital clinical trial (NCT03543306), it serves as a standard-of-care background therapy for patients undergoing surgical treatment for moderate to severe adhesions.

Other names

estradiol valerate + medroxyprogesterone acetateE2V + MPA